SABCS Highlights

Dr Aditya Bardia (Harvard Medical School, Boston, MA, USA) discusses the results of the phase III EMERALD trial, exploring elacestrant, an oral selective estrogen receptor degrader, vs investigator’s choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer following progression on prior endocrine and CDK4/6 inhibitor therapy. These results were presented at the San Antonio Breast […]

Dr Nancy Lin (Dana-Farber Cancer Institute, Boston, MA, USA) discusses the updated results of the phase II HER2CLIMB study, which assessed tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated HER2-positive metastatic breast cancer with brain metastases. These results were presented at the San Antonio Breast Cancer Symposium 2021. Questions 1. […]

Dr Marta Vaz Batista (Hospital Fernando Fonseca, Amadora, Portugal) discusses the preliminary results from the DEBBRAH phase II study, exploring trastuzumab deruxtecan in patients with HER2[+] or HER2-low-expressing advanced breast cancer and central nervous system involvement. These results were presented at the San Antonio Breast Cancer Symposium 2021. Questions 1. Could you tell us a […]

Professor David Potter (Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA) discusses the results of the I-SPY 2 trial, the evaluation of tucatinib + (paclitaxel + pertuzumab + trastuzumab) in high-risk HER2 positive stage II/III breast cancer. These results were presented at the San Antonio Breast Cancer Symposium 2021. Question: Please can you summarise […]

Professor Sara Hurvitz (David Geffen School of Medicine at UCLA, Los Angeles, CA, USA) discusses her presentation at the San Antonio Breast Cancer Symposium 2021 on the aims, efficacy and safety findings of the coopERA study. Questions 1. What is giredestrant, and what is the rationale for its use in HR+, HER2− early breast cancer? […]

Professor Sara Hurvitz (David Geffen School of Medicine at UCLA, Los Angeles, CA, USA) discusses her presentation at the San Antonio Breast Cancer Symposium 2021 on the aims, efficacy and safety findings of the TRINITI-1 study. Questions 1. What are the major unmet needs in the treatment of women with HR+, HER2− breast cancer? 00:12-02:06 […]

touchONCOLOGY joins Dr Javier Cortes at the San Antonio Breast Cancer Symposium (SABCS) 2020, to discuss the data being presented around the KEYNOTE-355 study and the potential of pembrolizumab as a treatment for triple-negative breast cancer (Clinical Trial Identifier: NCT02819518). The abstract ‘Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy […]

We had the pleasure to talk to Janine Simons (Erasmus University Medical Center, Rotterdam, Netherlands) about the RISAS study and its findings (Clinical Trial Identifier: NCT02800317). The abstract ‘Radioactive Iodine Seed placement in the Axilla with Sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer: Results of the prospective multicenter RISAS trial‘ (ABSTRACT NUMBER: […]

Tumours that are positive for human epidermal growth factor receptor 2 (HER2) are found in about 15–20% of all breast cancers.1 HER2 positivity is associated with aggressive tumours that are often high grade, with increased rates of growth, early metastasis and have, historically, been associated with reduced survival compared with other subtypes.1 The introduction of […]